Detailed Narrative
Q3 FY25 and Nine-Month Performance Highlights
Morepen Labs reported a 6.5% revenue increase for the nine months ended December 31, 2024, reaching ₹1,359 crores. Profitability saw significant improvement, with EBITDA margin up 21% and Profit After Tax (PAT) growing 44% to ₹97.71 crores for the nine-month period. For Q3 FY25, revenue stood at ₹458 crores, a modest 2% year-on-year growth and 3.45% quarter-on-quarter increase, with PAT at ₹27 crores and an EBITDA margin of 9.05%.
Medical Devices Segment: Robust Growth and Market Penetration
The Medical Devices segment demonstrated strong performance, growing 15% in Q3 FY25 to ₹123 crores, and 11% for the nine months to ₹394 crores. Glucometers and BP monitors constitute 90-95% of this business. The company has an installed base of 1.35 crore glucometers and sold 33 crore strips in nine months. BP monitor sales reached 9.5 lakh meters in nine months, up from 8.5 lakh last year, with the business now 100% indigenized, improving margins.
Pharma Business: Export-Driven Growth Amidst Pricing Pressures
The Pharma business recorded ₹966 crores in revenue for the nine months. Exports were a key driver, reaching a landmark ₹500 crores in nine months, a 9.9% increase from ₹455 crores last year. This growth was primarily fueled by a 55% jump in the European market. However, the API business faced margin pressure due to rising raw material costs and aggressive Chinese pricing, which has led to a strategic focus on higher-margin finished dosages and exports.
Capacity Expansion and New Product Initiatives
Morepen Labs is actively expanding its manufacturing capabilities. The civil work for the P8 API plant extension is complete, with 510 KL out of the planned 600 KL capacity already ready for production. Construction has also begun for the P9 block. In the OTC segment, the company launched 'LightLife' for weight management, featuring patented ingredients. Two new Rx products, Ticaspan (antiplatelet) and UdoFix (liver health), were also introduced, with UdoFix seeing demand in the government sector.
Geographical Performance and Market Outlook
Geographically, the US market experienced a 14% decline in nine months, attributed to political instability and election year effects. Conversely, the European market showed significant strength with a 55% revenue jump. The company strategically kept India market growth lower (down 5%) to prioritize profitability. Management anticipates overall revenue growth of 10-15% in the near term and a long-term CAGR of 20%, with a full-year FY25 revenue target of around ₹1,900 crores.
CDMO Business and Future Growth Drivers
The company is exploring opportunities in the Contract Development and Manufacturing Organization (CDMO) space. This strategy involves partnering with innovators who have R&D capabilities but lack large-scale manufacturing, leveraging Morepen's FDA-approved facilities and existing capacities. This move is aligned with the 'China plus one' model, aiming to capture high-end manufacturing from India and diversify beyond traditional B2B API sales into higher-value services.
Profitability Focus and Margin Outlook
Despite Q3 margin compression in the B2B API business due to raw material price increases not yet passed on, management reiterated its focus on improving overall profitability. The strategy involves increasing the share of higher-margin finished dosages and medical device exports. The company aims for an overall EBITDA margin of 11-12% in the coming year, driven by operational efficiencies and a favorable product mix.